Clients

Oramed Pharmaceuticals Inc.

Company Snapshot: Oramed Pharmaceuticals Inc.

ORMP
Last Change Volume High Low

Company Overview

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (POD™) technology is based on over 30 years of research by top scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The Company completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).

Client News

  1. Jan 27 2021 Oramed Issues Letter to Shareholders
  2. Jan 21 2021 Oramed Doses Patients Across Multiple Sites in Phase 3 Oral Insulin Study
  3. Jan 7 2021 Oramed to Present at H.C. Wainwright BioConnect 2021 Conference
  4. Dec 23 2020 Oramed Reports Positive First in Human Data from Oral Leptin Study